Remogliflozin etabonate

 Remogliflozin etabonate (INN/USAN)[1] is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV.[2] Remogliflozin was commercially launched first in India by Glenmark in May 2019.

Remogliflozin etabonate
Remogliflozin etabonate structure.svg
Clinical data
Routes of
administration		By mouth
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 5-Methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
CAS Number
  • 442201-24-3 check
ChemSpider
  • 8047110 ☒
UNII
  • TR0QT6QSUL
KEGG
  • D10055 ☒
ChEMBL
  • ChEMBL494323 ☒
CompTox Dashboard (EPA)
  • DTXSID50963191 Edit this at Wikidata
Chemical and physical data
FormulaC26H38N2O9
Molar mass522.595 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • OC1C(COC(=O)OCC)OC(C(O)C1O)Oc(nn(C(C)C)c2C)c2Cc3ccc(cc3)OC(C)C
InChI
  • InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1 ☒
  • Key:UAOCLDQAQNNEAX-ABMICEGHSA-N ☒
 ☒check (what is this?)  (verify)

Clinical trialsEdit

Remogliflozin etabonate was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels.[3][4] Remogliflozin etabonate has been studied at doses up to 1000 mg.[5] A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated.[6]

Method of actionEdit

Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[7] Remogliflozin is selective for SGLT2.

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.